BOTOX®/VISTABEL®
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Facial Corrections
Conditions
Facial Corrections, Facial Lines
Trial Timeline
Jan 5, 2023 → Oct 5, 2023
NCT ID
NCT05647551About BOTOX®/VISTABEL®
BOTOX®/VISTABEL® is a approved stage product being developed by AbbVie for Facial Corrections. The current trial status is completed. This product is registered under clinical trial identifier NCT05647551. Target conditions include Facial Corrections, Facial Lines.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05647551 | Approved | Completed |
Competing Products
13 competing products in Facial Corrections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX | AbbVie | Approved | 85 |
| OnabotulinumtoxinA + KYBELLA | AbbVie | Approved | 85 |
| Erenumab Prefilled Syringe | Amgen | Approved | 84 |
| Rapamune | Pfizer | Phase 1 | 32 |
| EMLA Cream | Sanofi | Phase 3 | 76 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 Placebo + Dysport | Ipsen | Phase 1/2 | 38 |
| IPN59011 + Azzalure + Placebo | Ipsen | Phase 1 | 30 |
| Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) | Baxter | Phase 2 | 49 |
| Metyrosine + Placebo | Bausch Health | Phase 2 | 47 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |